Pedretti - Google Patents
Dissecting the immune response elicited by PARP inhibitors in Homologous Recombination Repair altered breast cancerPedretti
View PDF- Document ID
- 8400046224693593931
- Author
- Pedretti F
External Links
Snippet
Breast cancer (BC) is the most diagnosed cancer globally and the leading cause of cancer- related deaths in women. Understanding the molecular heterogeneity of BC is crucial for improving treatment outcomes. Approximately 18% of BC exhibit alterations in the …
- 239000012661 PARP inhibitor 0 title abstract description 430
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Figueiredo et al. | Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development | |
Aoki et al. | Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma | |
EP3008173B1 (en) | Methods and compositions for reducing immunosupression by tumor cells | |
WO2018183921A1 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
Grizzi et al. | Evolving notions on immune response in colorectal cancer and their implications for biomarker development | |
Liu et al. | mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion | |
US11851712B2 (en) | Replication stress response biomarkers for immunotherapy response | |
US20210347847A1 (en) | Therapeutic targeting of malignant cells using tumor markers | |
Luo et al. | Ets transcription factor GABP controls T cell homeostasis and immunity | |
JP2023514441A (en) | Method for identifying functional disease-specific regulatory T cells | |
Hall et al. | Neoantigen-specific Cd4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic Melanoma patients | |
WO2020186101A1 (en) | Detection means, compositions and methods for modulating synovial sarcoma cells | |
Zak et al. | JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma | |
Maxwell et al. | ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity | |
Zhang et al. | Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia | |
Ghia et al. | Early stages in the ontogeny of small B‐cell lymphomas: genetics and microenvironment | |
US20230184771A1 (en) | Methods for treating bladder cancer | |
Pedretti | Dissecting the immune response elicited by PARP inhibitors in Homologous Recombination Repair altered breast cancer | |
Wienke et al. | Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy | |
US20220202811A1 (en) | Treatment for retinoic acid receptor-related orphan receptor Ɣ (rorƔ)-dependent cancers | |
Yang et al. | Comprehensive analyses reveal effects on tumor immune infiltration and immunotherapy response of APOBEC mutagenesis and its molecular mechanisms in esophageal squamous cell carcinoma | |
Zheng et al. | Multi-omics profiling identifies C1QA/B+ macrophages with multiple immune checkpoints associated with esophageal squamous cell carcinoma (ESCC) liver metastasis | |
Dang et al. | Single-cell transcriptomic profile reveals macrophage heterogeneity in medulloblastoma and their treatment-dependent recruitment | |
Ranti | HLA-E and NKG2A Mediate Resistance to M. Bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer | |
US20230398150A1 (en) | Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r |